Przejdź do zawartości
Merck
Wszystkie zdjęcia(1)

Kluczowe dokumenty

GE17-5280-02

nProtein A Sepharose 4 Fast Flow

Cytiva 17-5280-02, pack of 200 mL

Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych


About This Item

Kod UNSPSC:
41106500
NACRES:
NA.56

ligand

native protein A (S. aureus)

opakowanie

pack of 200 mL

producent / nazwa handlowa

Cytiva 17-5280-02

warunki przechowywania

(20% Ehtanol)

Matryca

4% cross-linked agarose

średnia średnica

90 μm (d50v)

Zakres roboczy

3-9

pojemność

>30 mg binding capacity(human IgG/ml)

przydatność

suitable for bioprocess medium

temp. przechowywania

2-8°C

Opis ogólny

nProtein A Sepharose 4 Fast Flow is native protein A coupled to Sepharose 4 Fast Flow for the purification of monoclonal and polyclonal antibodies at both laboratory and process scale.

nProtein A Sepharose 4 Fast Flow is native protein A coupled to the well established Sepharose 4 Fast Flow base matrix. The native protein A ligand is produced by fermenting a selected strain of Staphylococcus aureus. The purified protein is coupled to the cross-linked 4% agarose base matrix by the cyanogen bromide technique, giving a highly stable medium with minimal non-specific adsorption. nProtein A Sepharose 4 Fast Flow is manufactured without using animal-derived components.

nProtein A Sepharose 4 Fast Flow has nearly twice the total IgG binding capacity of Protein A Sepharose CL-4B, and is suitable for recovery and purification of monoclonal antibodies from cell culture at both laboratory and process scale. nProtein A Sepharose 4 Fast Flow was developed and tested in co-operation with leading manufacturers of purified monoclonal antibody products, and is used in routine commercial production.

As member of the BioProcess media range, nProtein A Sepharose 4 Fast Flow meets industrial demands with security of supply and comprehensive technical and regulatory support.

Cechy i korzyści

  • Replaces Protein A Sepharose 4 Fast Flow, the first Cytiva Protein A medium for large-scale purification of antibodies.
  • Used in routine commercial production of monoclonal antibodies
  • Free from animal-derived components.

Komentarz do analizy

To view the Certificate of Analysis for this product, please visit www.cytiva.com.

Informacje prawne

Sepharose is a trademark of Cytiva
Ta strona może zawierać tekst przetłumaczony maszynowo.

Piktogramy

Flame

Hasło ostrzegawcze

Warning

Zwroty wskazujące rodzaj zagrożenia

Zwroty wskazujące środki ostrożności

Kod klasy składowania

3 - Flammable liquids


Wybierz jedną z najnowszych wersji:

Certyfikaty analizy (CoA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumenty section.

Proszę o kontakt, jeśli potrzebna jest pomoc Obsługa Klienta

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

Monique G P van der Wijst et al.
Science translational medicine, 13(612), eabh2624-eabh2624 (2021-08-26)
Neutralizing autoantibodies against type I interferons (IFNs) have been found in some patients with critical coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the prevalence of these antibodies, their longitudinal dynamics across
Caleigh Mandel-Brehm et al.
Annals of neurology, 92(2), 279-291 (2022-04-26)
Rapid-onset Obesity with Hypothalamic Dysfunction, Hypoventilation and Autonomic Dysregulation (ROHHAD), is a severe pediatric disorder of uncertain etiology resulting in hypothalamic dysfunction and frequent sudden death. Frequent co-occurrence of neuroblastic tumors have fueled suspicion of an autoimmune paraneoplastic neurological syndrome
Sara E Vazquez et al.
eLife, 9 (2020-05-16)
The identification of autoantigens remains a critical challenge for understanding and treating autoimmune diseases. Autoimmune polyendocrine syndrome type 1 (APS1), a rare monogenic form of autoimmunity, presents as widespread autoimmunity with T and B cell responses to multiple organs. Importantly
Paul Bastard et al.
Science immunology, eabp8966-eabp8966 (2022-07-21)
Life-threatening 'breakthrough' cases of critical COVID-19 are attributed to poor or waning antibody response to the SARS-CoV-2 vaccine in individuals already at risk. Pre-existing autoantibodies (auto-Abs) neutralizing type I IFNs underlie at least 15% of critical COVID-19 pneumonia cases in

Produkty

This page shows various purification options for Protein A Sepharose chromatography media and describes typical binding and elution conditions for Protein A Sepharose chromatography media.

Na tej stronie przedstawiono różne opcje oczyszczania dla nośników do chromatografii z sefarozą Protein A oraz opisano typowe warunki wiązania i elucji dla nośników do chromatografii z sefarozą Protein A.

This page describes immunoprecipitation (immunoaffinity or pull-down techniques).

This page describes efficient column packing and preparation for affinity chromatography of antibodies.

Protokoły

This page provides information about different pull-down assays for the further isolation of multiprotein complexes to identify their components with products from Cytiva.

Ta strona zawiera informacje o różnych testach pull-down do dalszej izolacji kompleksów wielobiałkowych w celu identyfikacji ich składników za pomocą produktów Cytiva.

Protein A, coupled to Sepharose, binds IgG via its Fc regions, facilitating affinity chromatography purification.

This page shows how to separate IgG antibodies by affinity chromatography using Protein G Sepharose 4 Fast Flow from Cytiva.

Zobacz wszystko

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej